Providing solutions for professionals working in reproductive medicine
Board Certified and Full Professor of Obstetrics and Gynecology at the University of Valencia; Adjunct Clinical Professor, Department of Ob/Gyn, Stanford University School of Medicine, CA; Scientific Director of Instituto Valenciano de Infertilidad (IVI) and IGENOMIX.
Since 1991, his basic and clinical research has contributed to the advance of Reproductive Medicine, specifically in the understanding of human endometrial receptivity, embryo viability, embryonic implantation and endometriosis. He discovered the relevance of the interleukin-1 system in embryonic implantation (Simon et al., JCEM 1993; 1994; Endocrinology 1994; BOR 2006). He demonstrated the deleterious effect of high hormonal levels in patients with high response to gonadotrophins thus modifying the established clinical practice (HR1995; Fertil Steril 1996; 1998). He pioneered the concept that human oocytes are affected in endometriosis (HR 1994; Fertil Steril 2000) thus changing the clinical practice in oocyte donation. He proposed a new embryo coculture system, now successfully used worldwide (JCEM 1996; Fertil Steril 2003). His basic research on endometrial receptivity led him to create and patent a customized array named endometrial receptivity array (ERA) for the molecular diagnosis of endometrial receptivity (Fertil Steril 2011, 2013). He has been awarded “Prize Jaime I 2011 in Medical Investigation” for his pioneering work in human endometrial receptivity disorders.
In an independent bibliometric analysis considering publications in Reproductive Biology between 2003 and 2005, Carlos Simon was identified as the 9th most productive author in the world (Gonzalez-Alcaide G et al., Fertil Steril 90:941-56,2008).
Since 2001, he has expanded his research into the field of stem cells, resulting in the derivation, characterization, and registration in the Spanish National Stem Cell Bank (BNLC) of ten human embryonic stem cell (hESC) lines. He derived the first two hESC in Spain (Fertil Steril 2005) and described a new system for freezing hESC in the absence of animal contaminants. He derived VAL-6M, the first line with a monogenic disorder (Myotonic Dystrophy Type I) in Spain. Also, he obtained the first two hESC lines without destroying the human embryo using blastomere biopsy and demonstrated the lack of genetic diversity in the most common used hESC in the world (Mosher JT et al. N Engl J Med 2010). Finally, he reported the identification and characterization of human endometrial stem cells (Cervelló et al., PLoS ONE. 2010, 2011, 2012).
As Principal Investigator, his work has been funded through 16 projects sponsored by the Spanish Government, 4 by the Valencian Government, including 2 PROMETEO (granted to prestigious scientists) and 16 projects by international organizations, American Universities and private companies.
Metrics: At ISI Web of Knowledge Prof. Carlos Simon is author of 348 publications in international peer-review journals, adding up to an accumulated impact factor of 1,541.47. His papers have received a total of 11,139 cites with an average of 32 cites/paper. His H-Index is 60 and he is editor of 15 books. He has been Director of 28 PhD Thesis all qualified with “Cum Laude”, including 4 PhD Awards of Excellence and 3 European PhD. As inventor, his research has originated 13 Patent Applications, leading to the creation of IGENOMIX a biotech company.
As inventor, his research has originated 13 Patent Applications, leading to the creation of IGENOMIX a biotech company.
David earned a major in Business Science and an MBA from ESADE Business School. He is specialized in International Finance, with over 15 years of experience in consumer goods industries and 8 years in the health care industry. He has developed most of his career internationally, both in Europe and in America, working in Switzerland, US, Mexico and Spain.
He is an executive with broad private and public company backgrounds in both emerging and Fortune 500 companies. During his career, he has hold different responsibilities in Marketing, Finance, Business Development and IT providing him a wide view of business. David has been in general management for the last 8 years. He speaks fluent Spanish, English and French.
Since 2011, he has been the CEO of IGENOMIX, one of the leading companies in providing professional services in advanced molecular diagnoses in the reproductive medicine field.
Business Development Director Middle East & India
Francisco earned his MBA from IE Business School, Madrid and has a high degree in Industrial Engineering from Universidad de Navarra, Spain. He has over 12 years of experience and developed most of his career internationally.
Before joining Igenomix, he began his carrier working for PWC consulting company for more than 4 years, and then started helping leading companies in its internationalization process, establishing new subsidiaries and business units in Europe (Italy, France and Germany), US (California), and Asia (India, Japan and China). He has hold different responsibilities related to Planning and Finance, Business Strategy, Business Development and Marketing, providing him a wide view and experience. He speaks fluent Spanish and English.
For the last years, he has been the Business Developer Director for Asia and CEO of the recently launched subsidiary in India at IGENOMIX, one of the leading companies in providing professional services in advanced molecular diagnoses in the reproductive medicine field. Company belonging to the IVI Group.
Chief Financial Officer
Francisco B. Valor is a senior executive with more than 15 years of experience as a CFO. He has worked in privately-owned multinationals and public-listed companies in the chemical and food manufacturing sectors, as well as the healthcare services industry. He holds a B.A. of Business Administration from the University of Alicante (Spain) and earned his Executive MBA at the IESE Business School. He has extensive experience and knowledge of international and corporate finance and has helped companies go global in MEA, the USA, South America and Asia.
Lab Director Dubai
Dr. Rupali Chopra, PhD in Life Sciences from SMVDU, J&K, India carried out her thesis work under the supervision of Professor R.N.K. Bamezai, renowned Professor of Genetics and Director (Coordinator) National Centre of Applied Human Genetics, SLS, JNU, Delhi. has vast experience in the field of Human Genetics, population genetics, evolutionary genetics, mitochondrial diseases and forensic science with a strong background in Molecular biology, Genetics & Epigenetics.
Her technical expertise lie in a wide range of molecular biology applications with special emphasis on Sequencing, Genotyping, Gene Expression, Methylation analysis. She is also trained in sequencing and genotyping platforms (ABI), MassArray (Sequenom), real time PCR, and robotic workstations.
Her experience includes developing custom panels on Oncology (Mutational and Epigenetic profiling), Infectious disease panels, Prenatal Diseases (Trisomy21, Bthal, CFTR etc). Dr. Rupali has many peer reviewed publications as well.
Sruthi Warrier, Master in Technology in Molecular Medicine from Amrita Centre for Nanosciences and Molecular Medicine (ACNSMM), and Bachelor of technology in Biotechnology from Tamil Nadu Agricultural University.
Her experience includes microbiological and molecular biology studies related to diabetic and cancer patients.
Her technical expertise lie in a wide range of molecular biology applications with special emphasis on XRD, EDAX, RT-PCR, Sequencing, Microscopy, Gene Expression, Cell culture, etc.